The abstract is read at the publisher; the summary is JClub's.
CRISPR/Cas9–corrected endogenous hematopoietic stem and progenitor cells restore frataxin deficiency across brain, heart, and pancreas in a humanized mouse model of Friedreich’s ataxia.
- Why it matters: Gene therapy using adeno-associated viral vectors faces immune barriers, and direct correction of FXN deficiency in every affected tissue is difficult.
- What they did: Sivakumar et al. used CRISPR/Cas9 to excise the FXN repeat expansion ex vivo in HSPCs, then performed autologous transplantation and tracked long-term engraftment and multiorgan outcomes in a humanized FRDA mouse model.
- The result: A single systemic infusion of corrected HSPCs produced long-term engraftment and sustained multiorgan benefit, linked to myeloid progeny, supporting potential effectiveness in humans while bypassing direct tissue-by-tissue correction.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.